Home / About ACCC / Awards / ACCC Innovator Awards / 2023 Winners / Oncology Hematology Care

ONCOLOGY HEMATOLOGY CARE

Oncology Hematology Care

Molly Mendenhall, RN, BSN, Director of Quality and Compliance
Oncology Hematology Care, Inc. (OHC)
Cincinnati, Ohio


Closing the Testing Gap: Standardization of Comprehensive Biomarker Testing in NSCLC


A one-year quality improvement (QI) project implemented and standardized comprehensive biomarker testing in patients with metastatic non-small cell lung cancer (NSCLC). Custom data reports and monitoring dashboards ensured practice-wide adoption and sustainability across multiple clinic sites. After increasing biomarker testing rates from 68% to 92.7%, this QI project is now being scaled across the country through the US Oncology Network, McKesson as a best-practice initiative.


Watch Video

Featured Resources

A Model for Achieving Comprehensive Biomarker Testing in Non–Small Cell Lung Cancer

Nearly 70% of the positive biomarkers will have an impact on a patient’s first line treatment selection.

A Model for Achieving Comprehensive Biomarker Testing in Non–Small Cell Lung Cancer

From the ACCCBuzz Blog

ACCBuzz feature (6)

Closing the Testing Gap: Standardization of Comprehensive Biomarker Testing in NSCLC

August 25, 2023

Oncology Hematology Care, Inc. launched a one-year quality improvement project to implement and standardize comprehensive biomarker testing in patients with metastatic non-small cell lung cancer.